Radiation Oncology Institute launched with $5 million ASTRO grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

 

Theodore S. Lawrence, MD, PhD, from the University of Michigan in Ann Arbor and Colleen A. Lawton, MD, from the Medical College of Wisconsin in Milwaukee will lead the endowment campaign. Their goal is to raise $10 million in capital to build the infrastructure of the new ROI, according to ASTRO.

 

Once ROI is functional, it will serve as the chief philanthropic partner to ASTRO. Possible ROI programs include supporting research studies or impact analyses of new and existing treatment options; conducting outcomes studies on the efficacy and cost/ benefit of radiation therapy; and publishing radiation oncology-related trend data. ROI also will build a database of workforce and practice structures.

 

From ASTRO’s $5 million investment, $1 million will be used for an endowment and $1 million for initial seed funding.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.